A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder: CYP2D6 genetic testing and therapeutic drug monitoring.
10.7499/j.issn.1008-8830.2208092
- Author:
Di FU
1
;
Hong-Li GUO
1
;
Ya-Hui HU
1
;
Feng CHEN
1
Author Information
1. Pharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.
- Publication Type:Journal Article
- Keywords:
Atomoxetine;
Attention deficit hyperactivity disorder;
CYP2D6;
Child;
Precision medication
- MeSH:
Adult;
Child;
Humans;
Adrenergic Uptake Inhibitors/therapeutic use*;
Atomoxetine Hydrochloride/therapeutic use*;
Attention Deficit Disorder with Hyperactivity/genetics*;
Cytochrome P-450 CYP2D6/therapeutic use*;
Drug Monitoring;
Genetic Testing;
Propylamines/therapeutic use*;
Treatment Outcome
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(1):98-103
- CountryChina
- Language:Chinese
-
Abstract:
Atomoxetine is the first non-stimulant drug for the treatment of children and adults with attention deficit hyperactivity disorder (ADHD), and its safety and efficacy show significant differences in the pediatric population. This article reviews the genetic factors influencing the pharmacokinetic differences of atomoxetine from the aspect of the gene polymorphisms of the major metabolizing enzyme CYP2D6 of atomoxetine, and then from the perspective of therapeutic drug monitoring, this article summarizes the reference ranges of the effective concentration of atomoxetine in children with ADHD proposed by several studies. In general, there is an association between the peak plasma concentration of atomoxetine and clinical efficacy, but with a lack of data from the Chinese pediatric population. Therefore, it is necessary to establish related clinical indicators for atomoxetine exposure, define the therapeutic exposure range of children with ADHD in China, and combine CYP2D6 genotyping to provide support for the precision medication of atomoxetine.
